Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Levi Garraway

Tracked across 6 events · 65 articles · First seen Apr 21, 2026 · Last active Sep 24, 2026

Sentiment
13
Attention
8
Events
6
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
8 70
Business
Impact: Levi Garraway, Roche's chief medical officer, expressed confidence in bexobrutideg's potential to significantly advance treatment for complex blood cancers and other diseases, highlighting Roche's strategic vision for the drug.
Jun 07, 2026 · 22 articles
4 10
Tech
F. Hoffmann-La Roche — Genentech, a member of the Roche Group, and its partner Ionis Pharmaceuticals announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary…
Impact: As F. Hoffmann-La Roche — Genentech chief medical officer, Garraway publicly endorsed the interim data, lending clinical credibility to the sefaxersen results.
Sep 23, 2026 · 6 articles
6 0
Tech
Impact: Levi Garraway>>>, chief medical officer at F. Hoffmann-La Roche — Genentech>>>, provided commentary on the significance of giredestrant as a major advance in endocrine therapy for early-stage ER-positive breast cancer.
Jun 02, 2026 · 6 articles
6 0
Tech
Impact: Levi Garraway, as the chief medical officer and head of Global Product Development at F. Hoffmann-La Roche — Genentech, commented on the strength of the obesity portfolio and the potential for individualized treatment options.
May 27, 2026 · 19 articles
4 0
Regulatory
Impact: Levi Garraway>>>, Roche>>>'s Chief Medical Officer, commented on the significance of the filing acceptance for Atezolizumab>>>.
Jun 11, 2026 · 6 articles
2 0
Regulatory
Roche announced on 10 September 2026 that the United States — Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein…
Impact: Roche's Chief Medical Officer publicly highlighted the unmet need in MOGAD and Enspryng's potential, serving as the company's scientific spokesperson for the filing.
Sep 09, 2026 · 6 articles
Roche ↔ Levi Garraway
Roche ↔ Levi Garraway
ERGEN INTELLIGENCE
Track Levi Garraway live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.